Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Negative T790M Mutation and Met Amplification 1C-Met Exon 14 Mutation 1Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors 1

Interventions

glumetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × C-Met Exon 14 Mutation × glumetinib × Clear all
NCT04270591 2022-08-01

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Haihe Biopharma Co., Ltd.

Phase 1/2 Recruiting
183 enrolled

C-Met Exon 14 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡